SLC6A3 and Parkinson disease: Sharing of the molecular mechanisms (mitochondrial damage) and co-expression of the molecular targets (IR, GLUT2, DAT) on membranes of particular neurons as well as astrocytes might be the underlying mechanism for insulin-related metabolic alterations present in both AD and PD non-transgenic models.